Medpace shares plunge 8% as 2025 guidance disappoints

Published 10/02/2025, 22:46
Medpace shares plunge 8% as 2025 guidance disappoints

CINCINNATI - Medpace Holdings, Inc. (NASDAQ:MEDP) reported fourth-quarter earnings that beat analyst expectations, but its shares plunged 8.3% in after-hours trading Monday as the company’s 2025 revenue guidance fell short of estimates.

The contract research organization posted adjusted earnings per share of $3.67 for the fourth quarter, surpassing the analyst consensus of $2.94. Revenue came in at $536.6 million, slightly above the $534.86 million analysts had projected and up 7.7% from $498.4 million in the same quarter last year.

However, Medpace’s outlook for 2025 disappointed investors. The company forecasts full-year revenue between $2.11 billion and $2.21 billion, below the $2.238 billion analysts were expecting. This guidance implies growth of 0.0% to 4.8% over 2024 revenue of $2.109 billion.

For the fourth quarter, Medpace reported net new business awards of $529.7 million, down 13.8% year-over-year, resulting in a net book-to-bill ratio of 0.99x. The company’s backlog increased 3.2% to $2.90 billion as of December 31, 2024.

Medpace also announced its board approved a $600 million increase to its stock repurchase program. The company repurchased 527,160 shares at an average price of $330.43 per share for a total of $174.2 million during the fourth quarter.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.